Growth estimation of HPV and PAP testing market

During the projection period, the HPV testing and PAP test market is estimated to grow at a CAGR of 6.50 percent, with revenue of roughly USD 3550 million in 2020 and USD 5180 million by 2026. The market is being driven by an increase in the number of cervical cancer cases around the world, an increase in the number of cervical cancer screening programmes, and the development of advanced cervical cancer screening technologies.

With the developing COVID-19 pandemic over the world in 2020, numerous elective medical procedures, including cancer screening, were found to be mostly put on hold in order to prioritize more essential requirements and decrease the chance of COVID-19 spreading. This has resulted in a significant decrease in cancer screening. Once a result, as health systems recover, primary care appointments will reopen and preventive care measures will resume.

According to the World Health Organization, among women, cervical cancer is the fourth most common cancer, with an estimated 570,000 new cases in 2018, representing 6.6% of all female cancers. Approximately, 90% of deaths from cervical cancer occur in middle- to low-income countries.

Furthermore, the American Cancer Society expects that in the United States in 2019, 13,170 new instances of invasive cervical cancer were detected and 4,250 women died from cervical cancer. Furthermore, 951 females were diagnosed with cervical cancer in 2019, according to Cancer Australia.

The demand for cervical cancer screening programmes is increasing as the number of instances of cervical cancer rises. The tests have been discovered to resolve flaws in standard cervical screening, which has led to the development of alternative screening paradigms such as those based on detection of the human papillomavirus (HPV).Companies such as Qiagen NV offer technologically advanced HPV DNA detection tests, such as the Capture 2 test, which detects the presence of 13 high-risk HPV strains in a cervical sample. As a result, all of these factors have had an impact on the total market growth.

Key Market Trends

Cervical Cancer Screening Test is Expected to be the Dominant Over the Forecast Period

Cervical cancer screening is found to play and an essential part of a woman’s routine health care. For women with the age of 30 and above, an HPV test is being recommended for detection. The screening helps to identify precancerous lesions caused by HPV so they can be removed to prevent invasive cancers from developing.

Cervical cancer operations and screening were found to be delayed in 2020 due to the increased COVID-19 load, and only the most urgent procedures were conducted, affecting total market growth of HPV and PAP testing. Cancer diagnosis was found to be delayed as screening and diagnostic services were decreased or discontinued in many nations, but the situation is likely to improve post-pandemic with the availability of services being resumed which will show positive growth.

The major factor driving the growth of the segment include the rising burden of cervical cancer across the world. The disease is more commonly found in females. According to the World Health Organization, there are more than 270,000 women die every year due to cervical cancer.

According to the American Society of Clinical Oncology, approximately 13,170 women will be diagnosed with invasive cervical cancer in the United States in 2019. Because to an increase in screening, the disease's incidence rates reduced by more than half between 1975 and 2015, indicating that cervical cancer is on the rise every year. Cervical cancer can be prevented in the majority of instances by detecting and treating aberrant cell changes in the cervix years before cancer develops. As a result of the rising acceptance of early diagnosis, the market is predicted to develop at a healthy rate throughout the anticipated period.
The cervical cancer screening tests segment is thus found dominating the segment owing to the increasing awareness about the benefits associated with the early detection of cancer and the rising government support towards controlling the cervical cancer. Hence all these factors are expected to drive the market growth.